Quarterly report [Sections 13 or 15(d)]

REVENUES

v3.25.3
REVENUES
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES

 NOTE 10 – REVENUES

 

Disaggregation of Net Revenues

The Company’s net product revenues are summarized below:  

                 
   

Three months ended  

September 30, 

  
    2025   2024  
Zembrace Symtouch   $ 2,582   $ 2,485  
Tosymra     708     337  
Total product revenues   $ 3,290   $ 2,822  
                 
   

Nine months ended  

September 30, 

  
    2025   2024  
Zembrace Symtouch   $ 6,178   $ 6,059  
Tosymra     1,539     1,453  
Total product revenues   $ 7,717   $ 7,512  

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $7.0 million at September 30, 2025, of which $0.7 million was recorded as a reduction to accounts receivable and $6.3 million was recorded as a component of accrued expenses. Our provision for gross-to-net allowances was $4.8 million at September 30, 2024, of which $1.0 million was recorded as a reduction to accounts receivable and $3.8 million was recorded as a component of accrued expenses.